Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations

ResearchMoz added Latest Research Report titled " Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations " to it's Large Report database.

Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential glucose metabolism and leads to hyperglycemia (high blood glucose levels). As a result, immediate and lifelong treatment with exogenous insulin therapy is initiated upon diagnosis of T1DM. Exogenous insulin has remained the mainstay of T1DM therapy since it was used to treat the first human patient in 1922.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=494547

Consequently, insulin products comprise the vast majority of the T1DM market, which is largely monopolized by three big pharma players: Eli Lilly, Novo Nordisk and Sanofi. However, insulin treatment regimens are often inconvenient and are associated with undesirable side effects such as hypoglycemia (low blood glucose levels) and weight gain. In addition, there is a significant unmet need for more diversified treatment options including therapies capable of altering the clinical course of the pathological beta cell destruction and adjuvant therapies capable of improving glycemic control and reducing insulin requirements.

Scope

The report assesses the current T1DM market and forecasts market trends to 2021. Areas covered include -

An introduction to T1DM, which includes classification, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment
An analysis of the leading insulin therapies in the current T1DM marketed products landscape.
An analysis of the pipeline for T1DM. This includes a breakdown of pipeline molecules by stage of development, molecule type, route of administration, molecular target and novelty. Trends in T1DM clinical trial size, duration and failure rates, by molecule type and molecular target are discussed. A comparative analysis of the most promising pipeline molecules is also provided.

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 9
2.1 Disease Overview 9
2.2 Classification of Diabetes Mellitus 9
2.3 Symptoms 10
2.4 Etiology 11
2.4.1 Genetics 11
2.4.2 Age 11
2.4.3 Early Diet 11
2.4.4 Exposure to Infectious Agents 12
2.4.5 Vitamin D Deficiency 12
2.5 Pathophysiology 13
2.6 Epidemiology 15
2.7 Co-morbidities and Complications 16
2.7.1 Acute Metabolic Complications 16
2.7.2 Long-term Vascular Complications 17
2.7.3 Other Co-morbidities and Complications 19
2.8 Diagnosis 19
2.9 Treatment 20
2.9.1 Insulin Therapy 20
2.9.2 Non-insulin Adjunctive Therapy 22
2.9.3 Lifestyle Modifications 23

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.